Skip to content
Bull Bear Daily

Bull Bear Daily

Primary Menu
  • Home
  • Business
  • Domestic
  • Economy
  • Money
  • Politics
  • Top News
  • Newsletters
  • Home
  • 2026
  • June
  • 27
  • The GLP-1 Pill Just Got Approved. The Second-Order Trade Is Bigger.
  • Politics

The GLP-1 Pill Just Got Approved. The Second-Order Trade Is Bigger.

Eli Lilly's Foundayo changes who takes obesity drugs. The companies that benefit most aren't who you think.
Bull Bear Daily June 27, 2026 3 minutes read
d3f0f063-e451-4548-ae64-f69ad78f3137

The injection era for obesity drugs may not be ending. But it just got a serious competitor.

Here’s what happened. The FDA granted approval to orforglipron — now marketed as Foundayo — Eli Lilly’s once-daily oral GLP-1 receptor agonist for chronic weight management in adults with obesity or those overweight with at least one weight-related comorbidity. What makes this different from Novo Nordisk’s oral Wegovy, which launched in January? Foundayo is the first GLP-1 obesity pill with no food or water restrictions. You don’t have to take it on an empty stomach and wait 30 minutes. That sounds small. It isn’t.

Lilly’s CEO David Ricks put it plainly: “Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn’t serious enough for treatment.”

That number — 1 in 10 — is the only number that actually matters here. The entire market debate has been about Lilly vs. Novo. The bigger debate should be about the 90% of the addressable population who aren’t using any of these drugs at all.

The oral GLP-1 market is expected to capture around 20% of the $80 billion obesity GLP-1 market by the end of the decade. That’s $16 billion in a product category that barely existed 18 months ago. And that estimate was built before either pill was actually on pharmacy shelves.

Here’s where most investors are stopping the analysis. They’re tracking the horse race — Lilly vs. Novo, efficacy comparisons, pricing. In terms of efficacy, the Wegovy pill led to 13.6% weight loss in a 64-week Phase 3 trial, slightly more than the 11.2% weight loss orforglipron showed in its 72-week study. Novo wins on weight loss data. Lilly wins on convenience. And both of them win if the market expands, which it almost certainly will.

The part people are skipping is the downstream supply chain. Oral pills don’t require cold storage. They don’t require trained healthcare staff for administration. While the daily oral treatments are generally seen to be less effective than the weekly injectables, they’re still expected to have wide appeal since many people don’t want to use needles, and the pills can be easily distributed and don’t require cold storage.

That changes the distribution math entirely. Retail pharmacy becomes the front line. CVS, Walgreens, and specialty mail-order pharmacies suddenly matter more. The pharmacy benefit manager space gets repriced. Companies with the scale and infrastructure to handle high-volume, recurring oral prescriptions have a structural advantage that wasn’t there two years ago.

Lilly is also evaluating orforglipron in late-stage studies in other disease areas like obstructive sleep apnea, osteoarthritis pain of the knee, stress urinary incontinence, and hypertension. That pipeline expansion is the longer story. Foundayo’s obesity approval is the opening chapter.

GlobalData forecasts that orforglipron will claim status as a mega-blockbuster seller in 2031, bringing in sales of $13 billion during that year. That’s a projection. Projections are wrong. But the direction of travel here isn’t. Medicare Part D coverage begins July 1. The commercial savings card makes it accessible at $25 a month. The barriers that kept 90% of eligible patients on the sidelines are coming down, one by one.

The real question is not whether Lilly or Novo wins. It’s whether anyone is positioned for what happens when 30 million new patients start filling monthly prescriptions. That infrastructure question hasn’t been seriously priced.

Post navigation

Previous: Apple Just Hiked Prices on Its Biggest Products. The Stock Paid for It.
Next: Trump Accounts Launch in 7 Days. The Passive Flow Trade Is Already Here.

Related Stories

daf2ffbb-6e30-4538-8330-1a9647d03fa2
  • Politics

Trump Asked Xi to Buy More Soybeans. Whether It Sticks Is the Only Question That Matters.

Bull Bear Daily November 19, 2026
d4823353-8459-46c7-9738-0fdb1d60ed06
  • Politics

Disney’s $2 Dividend Looks Generous. Its Cash Flow Has to Back It Up.

Bull Bear Daily November 18, 2026
4ef43477-f46a-495a-ba75-f6c2874c8c25
  • Politics

Oracle Is the Question Mark Behind Every AI Debt Deal

Bull Bear Daily November 17, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Sign up for our free Bull Bear Daily Newsletter!

Discover new market trends and ideas directly to your inbox.

By providing your email, you agreed to receive informational and promotional messages from us. You may opt out at any time by clicking the unsubscribe at the bottom of each email. See our Privacy Policy for more information.

Recent Posts

  • Boeing Won’t Say Whether More Engineer Layoffs Are Coming. That’s the Real Production Update.
  • AI Stocks Are Down 74%. Their Bonds Flash the Same Warning.
  • Seven Down Days, One Key Number: Is the S&P 500 Correction All About Nvidia?
  • Accor’s €1.6bn Ennismore Bet Triggers a Fight for Its Future
  • Gap Earned 30% More on Flat Sales. Ross Grew Everything and Still Got Punished.
  • Intel Just Got Its First Real Foundry Customer
  • Nvidia’s China Wildcard: Can Trump’s Promise Beat Congress?

You may have missed

24a70d4d-94d3-4b9d-a493-6a06a0dc6407
  • Top News

Boeing Won’t Say Whether More Engineer Layoffs Are Coming. That’s the Real Production Update.

Bull Bear Daily November 22, 2026
9057dee4-4897-4013-b70c-40646dc33e81
  • Economy

AI Stocks Are Down 74%. Their Bonds Flash the Same Warning.

Bull Bear Daily November 21, 2026
21dafaee-9045-41a1-8e6c-0c23b4880888
  • Top News

Seven Down Days, One Key Number: Is the S&P 500 Correction All About Nvidia?

Bull Bear Daily November 21, 2026
b68d5628-4ac3-4848-97c5-a616be9e2ca9
  • Business

Accor’s €1.6bn Ennismore Bet Triggers a Fight for Its Future

Bull Bear Daily November 20, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us
Copyright 2026 © All rights reserved | Bull Bear Daily | bullbeardaily.com
SITE_OK
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}